← Back to headlines
Neurocrine Acquires Soleno for Drug Targeting Hunger Disorder
Neurocrine Biosciences is set to acquire Soleno Therapeutics, thereby gaining access to a promising drug designed to treat a relentless hunger disorder.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Philippines Announces Results of April 2026 Physicians Licensure Examination
just now
Pagasa flags 2 areas for dangerous heat index levels on April 9
just now
Philippines Experiences High Heat Index, DOH Issues Warnings as Areas Log Danger Levels
just now
Laguna Province Opens First Free Chemotherapy Center
just now